눈문/저서

1. [2015] Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer (ANTICANCER RESEARCH)
2. [2014] Genetic Polymorphism of miR-196a as a Prognostic Biomarker for Early Breast Cancer (ANTICANCER RESEARCH)
3. [2014] AQP5 Expression Predicts Survival in Patients with Early Breast Cancer (ANNALS OF SURGICAL ONCOLOGY)
4. [2013] A miR-146a Polymorphism (rs2910164) Predicts Risk of and Survival from Colorectal Cancer (ANTICANCER RESEARCH)
5. [2013] PPP1R13L variant associated with prognosis for patients with rectal cancer (JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY)
6. [2013] Functional Polymorphism in the MicroRNA-367 Binding Site as a Prognostic Factor for Colonic Cancer (ANTICANCER RESEARCH)
7. [2012] Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. (Leuk Lymphoma)
8. [2010] Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP (CANCER CHEMOTHERAPY AND PHARMACOLOGY)
9. [2009] TNF superfamily gene polymorphism as prognostic factor in early breast cancer (J Cancer Res Clin Oncol)
10. [2009] Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients (BONE MARROW TRANSPLANTATION)
11. [2008] Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors (AMERICAN JOURNAL OF HEMATOLOGY)
12. [2008] Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer (JOURNAL OF KOREAN MEDICAL SCIENCE)
13. [2008] Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer (Oncology-Basel)
14. [2007] Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. (Bone Marrow Transplant)